GATA2-Mutant Cells to Enable Cancer, Immunology, and Hematology Discoveries
Inventors: Emery Bresnick, Koichi Katsumura, Kirby Johnson
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing GATA2-enhancer mutant cells that retain the in vivo phenotype of considerably lower GATA2 expression than wild type immortalized fetal liver progenitor cells.
GATA-binding-factor 2 (GATA2) is a transcription factor involved in stem cell maintenance and hematopoietic development. The gene encoding GATA2 often suffers germline and somatic mutations, which result in a wide variety of inherited and acquired immune and blood disorders. There is a clear need to understand how disease mutants impact GATA2 protein function and lead to associated immune and blood disorders, such as immunodeficiency, bone marrow failure and leukemia.
UW-Madison researchers have developed a method to produce a GATA2-enhancer mutant (-77-/-) immortalized cell line. Immortalized hematopoietic cells can be isolated from the fetal livers of GATA2-enhancer mutant mice with the use of expressing ER-HOXB8. The GATA2-enhancer mutant cells retain the in vivo phenotype of considerably lower GATA2 expression than wild type immortalized fetal liver progenitor cells.
- Research tool for studying how GATA2 deficiencies disrupt hematopoiesis and lead to blood and immune disorders
- Express disease mutants to conduct genetic rescue analyses
- Development of therapeutics for modulating GATA2 deficiencies
- New method to produce GATA2-deficient cells
- Superior alternative to using cells taken immediately from mouse embryos with low GATA2 levels, which is expensive and low-throughput
- No comparable system exists to study these deficiencies
For More Information About the Inventors